[Comment] A turning point in the fight against ovarian cancer?

Ovarian cancer represents the fifth leading cause of death in women, with 5-year survival around 10%. This unfavourable prognosis figures are closely related to intrinsic or acquired resistance to conventional chemotherapy, making the active search of novel agents with relevant molecular targets crucial in the fight against this disease. In The Lancet Oncology, Jung-Min Lee and colleagues1 report the results of a phase 2 study investigating the clinical activity of prexasertib, a cell cycle checkpoint kinase 1 and 2 (CHK1 and CHK2) inhibitor, in recurrent high-grade serous ovarian cancer.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research